{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0.0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0.0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0.0"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"0","value":"0.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12300","upperLimit":"24200","value":"15750.0"},{"groupId":"OG001","lowerLimit":"30800","upperLimit":"73900","value":"55350.0"},{"groupId":"OG002","lowerLimit":"11000","upperLimit":"38300","value":"21750.0"},{"groupId":"OG003","lowerLimit":"16800","upperLimit":"49400","value":"33400.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"27600.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11100","upperLimit":"24100","value":"16550.0"},{"groupId":"OG001","lowerLimit":"26100","upperLimit":"67500","value":"50300.0"},{"groupId":"OG002","lowerLimit":"11000","upperLimit":"47200","value":"21100.0"},{"groupId":"OG003","lowerLimit":"17100","upperLimit":"50700","value":"29300.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"26900.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 2 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6320","upperLimit":"14500","value":"9235.0"},{"groupId":"OG001","lowerLimit":"16800","upperLimit":"37500","value":"27150.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 24 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1720","upperLimit":"9580","value":"4680.0"},{"groupId":"OG001","lowerLimit":"7800","upperLimit":"17900","value":"13000.0"},{"groupId":"OG002","lowerLimit":"3580","upperLimit":"13900","value":"7370.0"},{"groupId":"OG003","lowerLimit":"2400","upperLimit":"23500","value":"10000.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"13300.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CYCLE 1 DAY 4, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1290","upperLimit":"5080","value":"2320.0"},{"groupId":"OG001","lowerLimit":"3800","upperLimit":"6760","value":"5545.0"},{"groupId":"OG002","lowerLimit":"1520","upperLimit":"5930","value":"3910.0"},{"groupId":"OG003","lowerLimit":"1700","upperLimit":"11100","value":"4690.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"4870.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"0","upperLimit":"952","value":"476.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CYCLE 1 DAY 22, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"0","upperLimit":"1270","value":"570.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"2350.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CYCLE 1 DAY 29, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"6520","value":"0.0"},{"groupId":"OG001","lowerLimit":"525","upperLimit":"1600","value":"1230.0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"1510","value":"326.5"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"1880","value":"308.5"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"25800","value":"16900.0"},{"groupId":"OG001","lowerLimit":"27000","upperLimit":"65900","value":"47150.0"},{"groupId":"OG002","lowerLimit":"14000","upperLimit":"28600","value":"23100.0"},{"groupId":"OG003","lowerLimit":"20500","upperLimit":"64700","value":"30350.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"31400.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"863","upperLimit":"2980","value":"1380.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"1390.0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"28900","value":"0.0"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"1150","value":"287.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CYCLE 4 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13600","upperLimit":"26300","value":"20300.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"56600.0"},{"groupId":"OG002","lowerLimit":"17700","upperLimit":"27700","value":"22450.0"},{"groupId":"OG003","lowerLimit":"3440","upperLimit":"32200","value":"20050.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CYCLE 4 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1450","upperLimit":"3570","value":"2495.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"1430.0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"523","value":"0.0"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"1280","value":"780.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CYCLE 6 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14300","upperLimit":"30600","value":"20050.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"55900.0"},{"groupId":"OG002","lowerLimit":"20100","upperLimit":"27700","value":"24600.0"},{"groupId":"OG003","lowerLimit":"16700","upperLimit":"29000","value":"22450.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CYCLE 6 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"5190","value":"2810.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"1570.0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0.0"},{"groupId":"OG003","lowerLimit":"507","upperLimit":"553","value":"530.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CYCLE 9 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15900","upperLimit":"30100","value":"19100.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"53200.0"},{"groupId":"OG002","lowerLimit":"20300","upperLimit":"22800","value":"21550.0"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"15900","value":"7950.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CYCLE 9 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1160","upperLimit":"4790","value":"2225.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"2510.0"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"2020","value":"1010.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CYCLE 12 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19400","upperLimit":"31600","value":"27000.0"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"35000.0"},{"groupId":"OG003","lowerLimit":"7670","upperLimit":"13800","value":"10735.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CYCLE 12 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1500.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CYCLE 18 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"790.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CYCLE 30 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"6240","value":"570.0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"4070","value":"1130.0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"2380","value":"994.5"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"1850","value":"302.5"},{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual concentration for this single participant.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"END OF TREATMENT (~157 weeks),"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of belantamab mafodotin Antibody-Drug Conjugate (ADC). Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.","dispersionType":"Full Range","groups":[{"description":"In DE Phase, participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 0.95 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 100 mg nirogacestat administered twice a day (BID) on day 1, 4, 8 and 15 of 21-day cycles. Treatment was administered until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG000","title":"DE Phase: 0.95 mg/kg Belantamab Mafodotin + Nirogacestat"},{"description":"In DE Phase, participants with RRMM received 1.9 mg/ kg belantamab mafodotin IV infusion as powder for solution once Q3W infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 100 mg nirogacestat administered BID on day 1, 4, 8 and 15 of 21-day cycles. Treatment was administered until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG001","title":"DE Phase: 1.9 mg/kg Belantamab Mafodotin+ Nirogacestat"},{"description":"In DE Phase, participants with RRMM received 1.0 mg/ kg belantamab mafodotin IV infusion as powder for solution once every 4 weeks (Q4W) for Cycle 1-2 and then once every 8 weeks (Q8W) from Cycle 2 onwards, infused over 30- 60 minutes on day 1 of 28-day cycles in Q4W and 56-day cycle in Q8W in combination with 100 mg nirogacestat BID on day 1, 4, 8 and 15 of 21-day cycles. Treatment was administered until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG002","title":"DE Phase: 1.0 mg/kg Belantamab Mafodotin Q4W/Q8W + Nirogacestat BID"},{"description":"In DE Phase, participants with RRMM received 1.4 mg/ kg belantamab mafodotin IV infusion as powder for solution Q4W for Cycle 1 and then Q8W from Cycle2 onwards, infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 100 mg nirogacestat BID on day 1, 4, 8 and 15 of 21-day cycles. Treatment was administered until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG003","title":"DE Phase: 1.4 mg/kg Belantamab Mafodotin Q4W/Q8W + Nirogacestat BID"},{"description":"In DE Phase, participants with RRMM received 1.4 mg/ kg belantamab mafodotin IV infusion as powder for solution Q4W, infused over 30- 60 minutes on day 1 of 28-day cycles in combination with 100 mg nirogacestat BID on day 1, 4, 8 and 15 of 21-day cycles. Treatment was administered until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG004","title":"DE Phase: 1.4 mg/kg Belantamab Mafodotin Q4W + Nirogacestat BID"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic population included all participants in the safety population from whom at least one PK sample has been obtained and analysed. The \"0\" participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.","reportingStatus":"POSTED","timeFrame":"PRE-DOSE(PD), END OF INFUSION (EOI), EOI+2 HOURS(H), EOI+ 24H on Day(D) 1 of Cycle (C) 1; ANYTIME on C1 D4, D8, D22, and D29 ; PD and EOI on D1 of C2, C4, C6, C9, C12; PD on D1 of C18 and C30; End of Treatment (approximately 157 weeks)","title":"DE Phase: Plasma Concentrations of Belantamab Mafodotin Antibody-Drug Conjugate (ADC)","type":"SECONDARY","unitOfMeasure":"Nanogram/millilitre (ng/mL)"}